# Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults

> **NCT04818281** · PHASE1 · COMPLETED · sponsor: **Ihsan GURSEL, PhD, Prof.** · enrollment: 38 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 VLP Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04818281
- **Lead sponsor:** Ihsan GURSEL, PhD, Prof.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-27
- **Primary completion:** 2021-12-29
- **Final completion:** 2021-12-29
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818281, "Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04818281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*